Heart failure and acute myocardial infarction are conditions that are associated with high morbidity and mortality. Significant dysfunction of the heart muscle can occur as the consequence of end-stage chronic cardiovascular diseases or acute ischemic events that are marked by large infarction area and significant tissue necrosis. Despite the remarkable improvement of conventional treatments, a substantial proportion of patients still develops severe heart failure that can only be resolved by heart transplantation or mechanical device implantation. Therefore, novel approaches based on stem-cell therapy can directly modify the disease process and alter its prognosis. The ability of the stem-cells to modify and repair the injured myocardium is a challenging but intriguing concept that can potentially replace expensive and invasive methods of treatment that are associated with increased risks and significant financial costs. In that sense, granulocyte colony-stimulating factor (G-CSF) seems as an attractive treatment approach. Based on the series of pre-clinical experiments and a limited amount of clinical data, it was demonstrated that G-CSF agents possess the ability to mobilize stem-cells from bone marrow and induce their differentiation into cardiomyocytes or endothelial cells when brought into contact with injured regions of the myocardium. However, clinical benefits of G-CSF use in damaged myocardium remain unclear and are the topic of expert discussion. The main goal of this review is to present relevant and up-to-date evidence on G-CSF therapy use in pre-clinical models and in humans and to provide a rationale for its potential clinical applications in the future.
D'amario, D., Leone, A. M., Borovac, J. A., Cannata, F., Siracusano, A., Niccoli, G., Crea, F., Granulocyte colony-stimulating factor for the treatment of cardiovascular diseases: An update with a critical appraisal, <<PHARMACOLOGICAL RESEARCH>>, 2018; 127 (127): 67-76. [doi:10.1016/j.phrs.2017.06.001] [http://hdl.handle.net/10807/117004]
Autori: | ||
Titolo: | Granulocyte colony-stimulating factor for the treatment of cardiovascular diseases: An update with a critical appraisal | |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1016/j.phrs.2017.06.001 | |
Indirizzo URL alternativo: | http://www.elsevier.com/inca/publications/store/6/2/2/9/3/1/index.htt | |
Data di pubblicazione: | 2018 | |
Abstract: | Heart failure and acute myocardial infarction are conditions that are associated with high morbidity and mortality. Significant dysfunction of the heart muscle can occur as the consequence of end-stage chronic cardiovascular diseases or acute ischemic events that are marked by large infarction area and significant tissue necrosis. Despite the remarkable improvement of conventional treatments, a substantial proportion of patients still develops severe heart failure that can only be resolved by heart transplantation or mechanical device implantation. Therefore, novel approaches based on stem-cell therapy can directly modify the disease process and alter its prognosis. The ability of the stem-cells to modify and repair the injured myocardium is a challenging but intriguing concept that can potentially replace expensive and invasive methods of treatment that are associated with increased risks and significant financial costs. In that sense, granulocyte colony-stimulating factor (G-CSF) seems as an attractive treatment approach. Based on the series of pre-clinical experiments and a limited amount of clinical data, it was demonstrated that G-CSF agents possess the ability to mobilize stem-cells from bone marrow and induce their differentiation into cardiomyocytes or endothelial cells when brought into contact with injured regions of the myocardium. However, clinical benefits of G-CSF use in damaged myocardium remain unclear and are the topic of expert discussion. The main goal of this review is to present relevant and up-to-date evidence on G-CSF therapy use in pre-clinical models and in humans and to provide a rationale for its potential clinical applications in the future. | |
Lingua: | Inglese | |
Rivista: | ||
Citazione: | D'amario, D., Leone, A. M., Borovac, J. A., Cannata, F., Siracusano, A., Niccoli, G., Crea, F., Granulocyte colony-stimulating factor for the treatment of cardiovascular diseases: An update with a critical appraisal, <<PHARMACOLOGICAL RESEARCH>>, 2018; 127 (127): 67-76. [doi:10.1016/j.phrs.2017.06.001] [http://hdl.handle.net/10807/117004] | |
Appare nelle tipologie: | Articolo in rivista, Nota a sentenza |